• UCLA Health
  • myUCLAhealth
  • School of Medicine
U Magazine

U Magazine

U Magazine
  • Home
  • Current Issue
  • Centennial Campaign for UCLA Issue
  • Browse U Magazine
  • Letters to the Editor
  • Subscribe
  • Contact
  • UCLA Health
  • myUCLAhealth
  • School of Medicine

U Magazine

Browse U Magazine

  1. Home
  2. Browse U Magazine
Share this
The Cutting Edge

A One-Two Punch to Skin Cancer

Treating metastatic melanoma by combining immunotherapy with a drug that inhibits the cancer-spreading activity of a common gene mutation significantly increased survival times in an animal model.About 50 percent of patients with metastatic melanoma have the BRAF mutation and can be treated with vemurafenib.

In a study by researchers at UCLA's Jonsson Comprehensive Cancer Center, animals that received a combination of the recently approved BRAF inhibitor vemurafenib and an engineered T-cell immunotherapy had better tumor responses and lived more than twice as long as those getting the BRAF inhibitor or immunotherapy alone. The findings provide strong support for testing the combination therapy in human clinical trials.

About 50 percent of patients with metastatic melanoma have the BRAF mutation and can be treated with vemurafenib. More than 50 percent of them respond well to the drug, but the responses usually last only a few months. With immunotherapy, fewer patients respond, but the responses are more durable.

By pairing these therapies in a one-two punch, researchers hope to maintain the high response rates associated with vemurafenib and combine them with the longer disease-free progression times seen with immunotherapy, says Richard Koya, M.D., Ph.D., assistant professor of surgical oncology. "The idea was to target two different aspects of anti-cancer biology, hitting the tumor cells themselves with the BRAF inhibitor and adding in T-cells educated to induce a specific anti-tumor immune response. The results we saw in this study were very promising."

The study was published in the journal Cancer Research.

The researchers also found that the BRAF inhibitor helped boost the power of the immunotherapy, creating a greater combination effect, says co-author Antoni Ribas, M.D., Ph.D., professor of hematology/oncology. "We found that both treatments were more effective when administered together, and we were surprised to see that a drug that should only be targeting the BRAF-mutant cancer cells was also having a beneficial effect on the T-cells." It is vital to develop new drugs to treat metastatic melanoma, as few options are available for patients, the researchers said. Vemurafenib works well, but most patients eventually relapse.

"This is a patient population that we are not able to cure," Dr. Koya said. "With what we have now, we are just prolonging their lives. We need to have more options, and we hope this combination therapy proves to be an effective alternative."


Previous
Meditation Reduces Loneliness
Next
Barbara Natterson-Horowitz, M.D.


YOU ARE VIEWING

Winter 2013

Winter 2013
E-Brochure
Printable PDF
IN THIS ISSUE
  • Hope and Pride
  • Beating the Odds: "I'm Alive!"
  • Zeroing In on Autism Genes
  • ‘Breathing-Lung’ Transplant Makes History
  • What Makes Our Brains Human? It’s in the Wiring
  • 2,000 and Counting
  • TAVR Offers Alternative for Cardiac Patients Who Cannot Undergo Surgery
  • Can Obesity Help One to Survive Heart Failure?
  • Can Diet Help Heal Spinal-Cord Injury?
  • Ray of Hope in Fight against Duchenne MD
  • Meditation Reduces Loneliness
  • A One-Two Punch to Skin Cancer
  • Barbara Natterson-Horowitz, M.D.
  • Brain Trust
  • Three Who Stood Up
  • At Home in the Hospital
  • How Doctors Think
  • The Fashion Doctor
  • Awards/Honors
  • In Their Own Words: Tactical-Medicine Physicians
  • Postcard from Skid Row
  • MAA Alumnus of the Year
  • 2012-13 MAA Executive Board Members
  • On the Road
  • Calendar
  • Working Today for Today’s and Tomorrow’s Children
  • Raising Awareness of Ovarian Cancer
  • Events
  • Gifts
  • Chairs of Distinction
  • Lessons Learned: Get Up and Go See the Patient
Like Us on Facebook Follow Us on Twitter Subscribe to Our Videos on YouTube Follow us on Instagram Connect with Us on LinkedIn Follow us on Pinterest
UCLA Health hospitals ranked best hospitals by U.S. News & World Report
  • UCLA Health
  • Find a Doctor
  • School of Medicine
  • School of Nursing
  • UCLA Campus
  • Directory
  • Newsroom
  • Subscribe
  • Patient Stories
  • Giving
  • Careers
  • Volunteer
  • International Services
  • Privacy Practices
  • Nondiscrimination
  • Billing
  • Health Plans
  • Emergency
  • Report Broken Links
  • Terms of Use
  • 1-310-825-2631
  • Maps & Directions
  • Contact Us
  • Your Feedback
  • Report Misconduct
  • Get Social
  • Sitemap
Like Us on Facebook Follow Us on Twitter Subscribe to Our Videos on YouTube Follow us on Instagram Connect with Us on LinkedIn Follow us on Pinterest

Sign in to myUCLAhealth